@article{AMJ3856,
author = {Chenkui Miao and Aiming Xu and Yuxiao Zheng and Chao Liang and Jundong Zhu and Ye Tian and Binbin Ma and Panpan Lu and Weizhang Xu and Xiao Li},
title = {Association of STAT3 polymorphism with tyrosine kinase inhibitors-induced safety and efficacy in patients with metastatic renal cell carcinoma: a systematic review},
journal = {AME Medical Journal},
volume = {2},
number = {6},
year = {2017},
keywords = {},
abstract = {Background: To elucidate and summarize the safety and efficacy of signal transducer and activator of transcription (STAT) 3 polymorphism in tyrosine kinase inhibitors (TKIs)-treated patients with metastatic renal cell carcinoma (mRCC).
Methods: Relevant studies from PubMed, EMBASE and Web of Science were identified and included in this systematic review after elaborate screening. Odds ratios (ORs) with 95% confidence interval (CI) were applied to evaluate the correlation between STAT3 polymorphism and TKIs-induced events in mRCC.
Results: It was indicated that STAT3 polymorphism was associated with TKIs-induced events including stomatitis, hand-foot skin reactions (HFSR), and response in mRCC patients treated with TKIs. Considering its safety, STAT3 rs744166 was related to stomatitis development (n=1), and rs4796793 predicted the development and severity of HFSR (n=1). Furthermore, for its efficacy, STAT3 rs4796793, rs744166, and rs989119 were associated with treatment response (n=1).
Conclusions: Our systematic review revealed that STAT3 polymorphisms were associated with TKIs-induced safety and efficacy in patients with mRCC.},
issn = {2520-0518}, url = {https://amj.amegroups.org/article/view/3856}
}